Drug intelligence / Profile preview

aflibercept + alteplase

Development stage: Unknown
Lead developer: Regeneron Pharmaceuticals
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravitreal, Subretinal

Overview

A combination therapy used for the treatment of neovascular age-related macular degeneration (AMD) complicated by submacular hemorrhage. Aflibercept is a VEGF inhibitor that prevents neovascularization, while alteplase (recombinant tissue plasminogen activator or rtPA) dissolves blood clots by activating plasmin. When coapplied, alteplase helps clear the submacular hemorrhage while aflibercept addresses the underlying neovascular AMD.

Other names: aflibercept plus tissue plasminogen activatoraflibercept and tPAaflibercept and rtPA

Targets

PLG (Plasminogen)VEGFA (Vascular endothelial growth factor A)PGF (Placental Growth Factor)

Beyond the preview

Go deeper on aflibercept + alteplase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aflibercept + alteplase.

Explore the full profile